Pipeline

Therapeutic product candidates

Factor VIII Intolerance

Haemophilia A is a rare chronic bleeding disorder which leads to inadequate clotting of the blood in response to any type of injury or surgery.

Development of factor VIII inhibitors remains the biggest challenge in the treatment of haemophilia A. The development of inhibitors is due to loss of tolerance by the immune system to factor VIII sharply decreasing the efficacy of factor VIII and rendering the treatment ineffective.

Apitope’s ATX-F8-17 offers a potential first-in-class approach for both the treatment and prevention of factor VIII inhibitors. Apitope plans to partner ATX-F8-17 for further development.